Long-Term Decrease in VLA-4 Expression and Functional Impairment of Dendritic Cells during Natalizumab Therapy in Patients with Multiple Sclerosis

Myeloid and plasmacytoid dendritic cells (mDCs, pDCs) are central to the initiation and the regulation of immune processes in multiple sclerosis (MS). Natalizumab (NTZ) is a humanized monoclonal antibody approved for the treatment of MS that acts by blocking expression of VLA-4 integrins on the surf...

Descripción completa

Detalles Bibliográficos
Autores principales: de Andrés, Clara, Teijeiro, Roseta, Alonso, Bárbara, Sánchez-Madrid, Francisco, Martínez, M. Luisa, de Villoria, Juan Guzmán, Fernández-Cruz, Eduardo, Sánchez-Ramón, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319565/
https://www.ncbi.nlm.nih.gov/pubmed/22496780
http://dx.doi.org/10.1371/journal.pone.0034103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319565/
https://www.ncbi.nlm.nih.gov/pubmed/22496780
http://dx.doi.org/10.1371/journal.pone.0034103

Ejemplares similares